Ç÷°ü³»ÇÇ ±â´ÉÀÇ Æò°¡-¼øÈ¯±âÁúȯ °ü¸®¿¡ Ȱ¿ëÇÒ Æò°¡¿Í ½ÇÁ¦
- ÀúÀÚ(±Û)±è¿ø ¿Ü
- ÃâÆÇ»ç´ëÇÑÀÇÇÐ
- ¹ßÇàÀÏ2017³â 11¿ù 17ÀÏ
½ÉÇ÷°ü ÁßÀç½Ã¼úÀÇ Çõ½ÅÀ» À̲ô´Â ¸®´õ
ÇãÇ÷¼º ½ÉÀåÁúȯ°ú ¸»ÃÊÇ÷°ü Áúȯ ºÐ¾ßÀÇ Àü¹®°¡·Î ¼Õ²ÅÈ÷´Â ±è¿ø ±³¼ö´Â ÃֽŠÁßÀç½Ã¼ú ±â¹ýÀ» µµÀÔÇÏ¿© ȯÀÚµéÀÇ Ä¡·á ¼º°ú¸¦ ³ôÀ̰í ÀÖ´Ù. ´ÙÇÐÁ¦Àû Á¢±ÙÀ» ÅëÇØ º¹ÀâÇÑ ½ÉÇ÷°ü Áúȯ¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ Ä¡·á Àü·«À» ¼ö¸³Çϸç, Áö¼ÓÀûÀÎ ¿¬±¸¸¦ ÅëÇØ »õ·Î¿î Ä¡·á¹ý °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ´Ù. ±¹³»¿Ü Çмú Ȱµ¿À» ÅëÇØ ½ÉÇ÷°ü ÀÇÇÐ ¹ßÀüÀ» ¼±µµÇϰí ÀÖ´Ù.
| Á¦ ¸ñ | ¼øÈ¯±â ÀÓ»ó Ã߸®ÀÇ ºñ¹ý | ||
|---|---|---|---|
| ÃâÆÇ»ç | ¹ßÇàÀÏ | 2014³â 07¿ù | |
| Á¦ ¸ñ | Low-Dose Triple Antihypertensive Combination Therapy in Patients with Hypertension: A Randomized, Double-Blind, Phase II Study | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2020³â | ¹ßÇ¥Áö | |
| Á¦ ¸ñ | Neointima characteristics as a prognostic marker for drug-coated balloon angioplasty in patients with in-stent restenosis: an optical coherence tomography study | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2020³â | ¹ßÇ¥Áö | |
| Á¦ ¸ñ | Effect of Ticagrelor on Left Ventricular Remodeling in Patients With ST-Segment Elevation Myocardial Infarction (HEALING-AMI) | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2020³â | ¹ßÇ¥Áö | |
| Á¦ ¸ñ | 2020 Korean Society of Myocardial Infarction Expert Consensus Document on Pharmacotherapy for Acute Myocardial Infarction | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2020³â | ¹ßÇ¥Áö | |
| Á¦ ¸ñ | BAY60-2770 attenuates doxorubicin-induced cardiotoxicity by decreased oxidative stress and enhanced autophagy | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2020³â | ¹ßÇ¥Áö | |
| Á¦ ¸ñ | Long-Term Clinical Effects of Carotid Intraplaque Neovascularization in Patients with Coronary Artery Disease | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2020³â | ¹ßÇ¥Áö | |
| Á¦ ¸ñ | Troponin Aptamer on an Atomically Flat Au Nanoplate Platform for Detection of Cardiac Troponin I | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2020³â | ¹ßÇ¥Áö | |

°æÈñ´ëÇб³º´¿øÀº ȯÀÚ Áß½ÉÀÇ ÀÇ·á ¼ºñ½º¸¦ Á¦°øÇϸç, ±¹³» ÀÇ·á°è¸¦ ¼±µµÇÏ´Â »ó±ÞÁ¾ÇÕº´¿øÀÔ´Ï´Ù. ÃֽŠÀÇ·á ±â¼ú°ú Àåºñ¸¦ Ȱ¿ëÇÏ¿© ȯÀڵ鿡°Ô ÃÖ»óÀÇ Ä¡·á¸¦ Á¦°øÇÕ´Ï´Ù. ƯÈ÷ ÁßÁõÁúȯ Ä¡·á ¹× ¿¬±¸¿¡ °Á¡À» º¸À̸ç, ´ÙÇÐÁ¦ ÇùÁø ½Ã½ºÅÛÀ» ÅëÇØ ȯÀÚÀÇ °Ç°À» ÃÖ¿ì¼±À¸·Î »ý°¢ÇÕ´Ï´Ù. °æÈñ´ëÇб³º´¿øÀº ȯÀÚµéÀÇ ½Å·Ú¿Í ¸¸Á·µµ¸¦ ³ôÀÌ´Â µ¥ ÁÖ·ÂÇϸç, Áö¼ÓÀûÀ¸·Î ÀÇ·á ǰÁú Çâ»ó°ú ¿¬±¸ °³¹ß¿¡ Èû¾²°í ÀÖ½À´Ï´Ù.
¼¿ïƯº°½Ã µ¿´ë¹®±¸ °æÈñ´ë·Î 23 °æÈñ´ëÇб³º´¿ø